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Abstract
The Juvenile Arthritis Multidimensional Assessment Report (JAMAR) is a new parent/patient-reported outcome measure 
that enables a thorough assessment of the disease status in children with juvenile idiopathic arthritis (JIA). We report the 
results of the cross-cultural adaptation and validation of the parent and patient versions of the JAMAR in the Greek language. 
The reading comprehension of the questionnaire was tested in 10 JIA parents and patients. Each participating centre was 
asked to collect demographics, clinical data, and the JAMAR from 100 consecutive JIA patients or all consecutive patients 
seen in a 6-month period and to administer the JAMAR to 100 healthy children and their parents. The statistical validation 
phase explored descriptive statistics and the psychometric issues of the JAMAR: the three Likert assumptions, floor/ceiling 
effects, internal consistency, Cronbach’s alpha, interscale correlations, test–retest reliability, and construct validity (conver-
gent and discriminant validity). The Greek JAMAR was fully cross-culturally adapted with two forward and three backward 
translations. A total of 272 JIA patients (5.9% systemic, 57.7% oligoarticular, 21.3% RF negative poly-arthritis, 15.1% other 
categories), and 100 healthy children were enrolled in all centres. The JAMAR components discriminated well-healthy 
subjects from JIA patients; notably, there was no significant difference between healthy subjects and their affected peers in 
psychosocial quality of life and school-related items. All JAMAR components revealed good psychometric performances. 
In conclusion, the Greek version of the JAMAR is a valid tool for the assessment of children with JIA and is suitable for use 
both in routine clinical practice and in clinical research.
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Introduction
The aim of the present study was to cross-culturally adapt 
and validate the Greek parent, child/adult version of the 
Juvenile Arthritis Multidimensional Assessment Report 
(JAMAR) [1] in patients with juvenile idiopathic arthritis 
(JIA). The JAMAR assesses the most relevant parent/patient-
reported outcomes in JIA, including overall well-being, 
functional status, health-related quality of life (HRQoL), 
pain, morning stiffness, disease activity/status/course, 
articular and extra-articular involvement, drug-related side 
effects/compliance, and satisfaction with illness outcome.
This project was part of a larger multinational study con-
ducted by the Paediatric Rheumatology International Trials 
Organisation (PRINTO) [2] aimed to evaluate the Epide-
miology, Outcome and Treatment of Childhood Arthritis 
(EPOCA) in different geographic areas [3].
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We report herein the results of the cross-cultural adapta-
tion and validation of the parent and patient versions of the 
JAMAR in the Greek language.
Materials and methods
The methodology employed has been described in detail in 
the introductory paper of the supplement [4]. In brief, it was 
a cross-sectional study of JIA children, classified according 
to the ILAR criteria [5, 6] and enrolled from February 2012 
to April 2014. Children were recruited after Ethics Commit-
tee approval and consent from at least one parent.
The JAMAR
The JAMAR [1] includes the following 15 sections:
 1. Assessment of physical function (PF) using 15 items 
in which the ability of the child to perform each task is 
scored as follows: 0 = without difficulty, 1 = with some 
difficulty, 2 = with much difficulty, and 3 = unable to 
do and not applicable if it was not possible to answer 
the question or the child was unable to perform the 
task due to their young age or to reasons other than 
JIA. The total PF score ranges from 0 to 45 and has 
three components: PF-lower limbs (PF-LL); PF-hand 
and wrist (PF-HW); and PF-upper segment (PF-US) 
each scoring from 0 to 15 [7]. Higher scores indicating 
higher degree of disability [8–10].
 2. Rating of the intensity of the patient’s pain on a 
21-numbered circle visual analogue scale (VAS) [11].
 3. Assessment of the presence of joint pain or swelling 
(present/absent for each joint).
 4. Assessment of morning stiffness (present/absent).
 5. Assessment of extra-articular symptoms (fever and 
rash) (present/absent).
 6. Rating of the level of disease activity on a 21-circle 
VAS.
 7. Rating of disease status at the time of the visit (cat-
egorical scale).
 8. Rating of disease course from previous visit (categori-
cal scale).
 9. Checklist of the medications the patient is taking (list 
of choices).
 10. Checklist of side effects of medications.
 11. Report of difficulties with medication administration 
(list of items).
 12. Report of school/university/work problems caused by 
the disease (list of items).
 13. Assessment of HRQoL, through the Physical Health 
(PhH), and Psychosocial Health (PsH) sub-scales (five 
items each) and a total score. The four-point Likert 
response, referring to the prior month, are ‘never’ 
(score = 0), ‘sometimes’ (score = 1), ‘most of the time’ 
(score = 2) and ‘all the time’ (score = 3). A ‘not assess-
able’ column was included in the parent version of the 
questionnaire to designate questions that cannot be 
answered because of developmental immaturity. The 
total HRQoL score ranges from 0 to 30, with higher 
scores indicating worse HRQoL. A separate score for 
PhH and PsH (range 0–15) can be calculated [12–14].
 14. Rating of the patient’s overall well-being on a 21-num-
bered circle VAS.
 15. A question about satisfaction with the outcome of 
the illness (yes/no) [15]. The JAMAR is available in 
three versions, one for parent proxy-report (child’s age 
2–18), one for child self-report, with the suggested age 
range of 7–18 years, and one for adults.
Cross‑cultural adaptation and validation
The process of cross-cultural adaptation was conducted 
according to international guidelines with 2–3 forward and 
backward translations. In those countries for which the trans-
lation of JAMAR had been already cross-cultural adapted in 
a similar language (i.e., Spanish in South American coun-
tries), only the probe technique was performed. Reading 
comprehension and understanding of the translated ques-
tionnaires were tested in a probe sample of ten JIA parents 
and ten patients.
Each participating centre was asked to collect demo-
graphic, clinical data, and the JAMAR in 100 consecutive 
JIA patients or all consecutive patients seen in a 6-month 
period and to administer the JAMAR to 100 healthy children 
and their parents.
The statistical validation phase explored the descriptive 
statistics and the psychometric issues [16]. In particular, we 
evaluated the following validity components: the first Lik-
ert assumption (mean and standard deviation [SD] equiva-
lence); the second Likert assumption or equal item-scale 
correlations (Pearson r: all items within a scale should con-
tribute equally to the total score); third Likert assumption 
(item internal consistency or linearity for which each item 
of a scale should be linearly related to the total score that is 
90% of the items should have Pearson r ≥ 0.4); floor/ceiling 
effects (frequency of items at lower and higher extremes of 
the scales, respectively); internal consistency, measured by 
the Cronbach’s alpha, interscale correlation (the correlation 
between two scales should be lower than their reliability 
coefficients, as measured by Cronbach’s alpha); test–retest 
reliability or intra-class correlation coefficient (reproducibil-
ity of the JAMAR repeated after 1 or 2 weeks); and construct 
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validity in its two components: the convergent or external 
validity which examines the correlation of the JAMAR sub-
scales with the 6 JIA core set variables, with the addition 
of the parent assessment of disease activity and pain by the 
Spearman’s correlation coefficients (r) [17] and the discri-
minant validity, which assesses whether the JAMAR dis-
criminates between the different JIA categories and healthy 
children [18]. Quantitative data were reported as medians 
with first and third quartiles and categorical data as absolute 
frequencies and percentages.
The complete Greek parent and patient versions of the 
JAMAR are available upon request to PRINTO.
Results
Cross‑cultural adaptation
The Greek JAMAR was fully cross-culturally adapted from 
the standard English version with two forward and three 
backward translations with a concordance for 117/123 
(95.1%) translations lines for the parent version and 115/120 
(95.8%) lines for the child version. Of the 123 lines in the 
parent version of the JAMAR, 119 (96.7%) were understood 
by at least 80% of the ten parents tested (median = 100%; 
quartiles: 30–100%). In the patient version of the JAMAR, 
116/120 (95.8%) lines were understood by at least 80% of 
the children (median = 100%; quartiles: 30–100%). Lines 1, 
27, 40, and 51 of the JAMAR parent version were modified 
according to parents’ suggestions and lines 1, 25, 38, and 49 
of the JAMAR patient version were modified according to 
children observations in the probe technique.
Demographic and clinical characteristics 
of the subjects
A total of 275 JIA patients and 100 healthy children (total 
of 375 subjects) were enrolled at all participating paediatric 
rheumatology centres. Three patients did not give the con-
sent to use their data.
In the 272/275 (99%) JIA subjects, the JIA categories 
were 5.9% with systemic arthritis, 57.7% with oligoarthritis, 
21.3% with RF negative poly-arthritis, 0.4% with RF posi-
tive poly-arthritis, 2.9% with psoriatic arthritis, 5.9% with 
enthesitis-related arthritis, and 5.9% with undifferentiated 
arthritis (Table 1).
A total of 366/372 (98.4%) subjects had the parent ver-
sion of the JAMAR completed by a parent (267 from parents 
of JIA patients and 99 from parents of healthy children). The 
JAMAR was completed by 285/366 (77.9%) mothers and 
81/366 (22.1%) fathers. The child version of the JAMAR 
was completed by 242/372 (65.1%) children age 5.4 or older. 
In addition, patients younger than 7 years, capable to assess 
their personal condition and able to read and write, were 
asked to fill in the patient version of the questionnaire.
Discriminant validity
The JAMAR results are presented in Table 1, including the 
scores [median (first–third quartiles)] obtained for the PF, 
the PhH, the PsH sub-scales, and total score of the HRQoL 
scales. The JAMAR components discriminated well between 
healthy subjects and JIA patients.
In summary, the JAMAR revealed that JIA patients had 
a greater level of disability and pain, as well as a lower 
HRQoL than their healthy peers. However, there was no 
significant difference between healthy subjects and their 
affected peers in psychosocial quality of life and school-
related items.
Psychometric issues
The main psychometric properties of both parent and child 
versions of the JAMAR are reported in Table 2. The follow-
ing “Results” section refers mainly to the parent’s version 
findings, unless otherwise specified.
Descriptive statistics (first Likert assumption)
For all JAMAR items, the median number of missing 
responses was 0.6 (0.0–1.9).
The response pattern for both PF and HRQoL was posi-
tively skewed toward normal functional ability and normal 
HRQoL. All response choices were used for the different 
HRQoL items except for items 1 and 8, whereas a reduced 
number of response choices were used for all the PF items, 
except for items 1, 3, 4, 7, and 11. The mean and SD of the 
items within a scale were roughly equivalent for the PF and 
for the HRQoL items (data not shown). The median number 
of items marked as not applicable was 1% (0–1%) for the PF 
and 4% (2–7%) for the HRQoL.
Floor and ceiling effect
The median floor effect was 94.8% (92.5–95.9%) for the PF 
items, 78.3% (71.5–82.0%) for the HRQoL-PhH items, and 
78.3% (73.0–83.1%) for the HRQoL-PsH items. The median 
ceiling effect was 0.0% (0–0.4%) for the PF items, 0.7% 
(0.4–1.9%) for the HRQoL-PhH items, and 1.1% (0.7–1.1%) 
for the HRQoL-PsH items. The median floor effect was 
67.4% for the pain VAS, 59.2% for the disease activity VAS, 
and 66.7% for the well-being VAS. The median ceiling effect 
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was 0.0% for the disease activity VAS, 3.4% for the well-
being VAS, and 0.4% for the pain VAS.
Equal item‑scale correlations (second Likert 
assumption)
Pearson item-scale correlations corrected for overlap were 
roughly equivalent for items within a scale for 87% of the PF 
items, with the exception of PF items 11 and 15, and for 80% 
of the HRQoL items, with the exception of items 1 and 8.
Items internal consistency (third Likert assumption)
Pearson item-scale correlations were ≥ 0.4 for 87% of items 
of the PF (except for PF items 11 and 15) and 100% of items 
of the HRQoL.
Table 2  Main psychometric characteristics between the parent and child versions of the JAMAR
JAMAR Juvenile Arthritis Multidimensional Assessment Report; JIA juvenile idiopathic arthritis; VAS visual analogue scale; PF physical func-
tion; HRQoL Health-Related Quality of Life; PhH Physical Health; PsH Psychosocial Health; PF-LL PF-lower limbs; PF-HW PF-hand and 
wrist; PF-US PF-upper segment
Parent N = 267/366 Child N = 143/243
Missing values (first–third quartiles) 0.6 (0.0–1.9) 0.7 (0.0–1.7)
Response pattern PF and HRQoL positively skewed PF and HRQoL positively skewed
Floor effect, median
 PF (%) 94.8 93.7
 HRQoL-PhH (%) 78.3 79.0
 HRQoL-PsH (%) 78.3 76.2
 Pain VAS (%) 67.4 58.0
 Disease activity VAS (%) 59.2 60.8
 Well-being VAS (%) 66.7 60.1
Ceiling effect, median
 PF (%) 0.0 0.0
 HRQoL-PhH (%) 0.7 0.7
 HRQoL-PsH (%) 1.1 0.7
 Pain VAS (%) 0.0 0.0
 Disease activity VAS (%) 3.4 0.7
 Well-being VAS (%) 0.4 0.0
Items with equivalent item-scale correlation 87% for PF, 80% for HRQoL 87% for PF, 93% for HRQoL
Items with item-scale correlation ≥ 0.4 87% for PF, 100% for HRQoL 87% for PF, 100% for HRQoL
Cronbach’s alpha
 PF-LL 0.86 0.77
 PF-HW 0.85 0.84
 PF-US 0.73 0.63
 HRQoL-PhH 0.86 0.87
 HRQoL-PsH 0.76 0.80
Items with item-scale correlation lower than the Cronbach alpha 100% for PF, 100% for HRQoL 100% for PF, 100% for HRQoL
Test–retest intra-class correlation
 PF total score 0.66 0.74
 HRQoL-PhH 0.0 0.29
 HRQoL-PsH 1.0 0.97
Spearman correlation with JIA core-set variables, median
 PF 0.5 0.5
 HRQoL-PhH 0.5 0.5
 HRQoL-PsH 0.3 0.3
 Pain VAS 0.5 0.5
 Disease activity VAS 0.4 0.5
 Well-being VAS 0.4 0.5
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Cronbach’s alpha internal consistency
Cronbach’s alpha was 0.86 for PF-LL, 0.85 for PF-HW, and 
0.73 for PF-US. Cronbach’s alpha was 0.86 for HRQoL-PhH 
and 0.76 for HRQoL-PsH.
Interscale correlation
The Pearson correlation of each item of the PF and the 
HRQoL with all items included in the remaining scales of 
the questionnaires was lower than the Cronbach’s alpha.
test–retest reliability
Reliability was assessed in ten JIA patients, by re-adminis-
tering both versions (parent and child) of the JAMAR after 
a median of 8 days (7–9 days). The intra-class correlation 
coefficients (ICC) for the PF total score showed a substan-
tial reproducibility (ICC = 0.66). The ICC for the HRQoL-
PhH showed a poor reproducibility (ICC = 0.0) and for the 
HRQoL-PsH showed an almost perfect reproducibility 
(ICC = 1.0).
Convergent validity
The Spearman correlation of the PF total score with the 
JIA core set of outcome variables ranged from 0.4 to 0.5 
(median = 0.5). The PF total score best correlation was 
observed with the parent assessment of pain (r = 0.6, 
p < 0.001). For the HRQoL, the median correlation of the 
PhH with the JIA core set of outcome variables ranged from 
0.4 to 0.6 (median = 0.5), whereas for the PsH ranged from 
0.2 to 0.3 (median = 0.3). The PhH showed the best correla-
tion with the parent’s assessment of pain (r = 0.7, p < 0.001) 
and the PsH with the parent global assessment of well-being 
(r = 0.5, p < 0.001). The median correlations between the 
pain VAS, the well-being VAS, and the disease activity VAS 
and the physician-centred and laboratory measures were 0.5 
(0.3–0.6), 0.4 (0.3–0.5), and 0.4 (0.3–0.5), respectively.
Discussion
In this study, the Greek version of the JAMAR was cross-
culturally adapted from the original standard English version 
with two forward and three backward translations. Accord-
ing to the results of the validation analysis, the Greek parent 
and patient versions of the JAMAR possess satisfactory psy-
chometric properties. The disease-specific components of 
the questionnaire discriminated well between patients with 
JIA and healthy controls. Notably, there was no significant 
difference between the healthy subjects and their affected 
peers in the psychosocial quality of life and school-related 
problems. These findings indicate that children with JIA 
adapt well to the consequences of JIA, and have school per-
formances comparable to those of their healthy peers. Psy-
chometric performances were good for all domains of the 
JAMAR with few exceptions: two PF items (stretch arms and 
bite a sandwich or an apple) showed a lower item’s internal 
consistency. However, the overall internal consistency was 
excellent for all the domains.
In the external validity evaluation, the Spearman’s cor-
relations of the PF and HRQoL scores with JIA core set 
parameters were moderate.
The results obtained for the parent version of the JAMAR 
are very similar to those obtained for the child version, 
which suggests that children are equally reliable proxy 
reporters of their disease and health status as their parents. 
The JAMAR is aimed to evaluate the side effects of medi-
cations and school attendance, which are other dimensions 
of daily life that were not previously considered by other 
HRQoL tools. This may provide useful information for inter-
vention and follow-up in health care.
In conclusion, the Greek version of the JAMAR was 
found to have satisfactory psychometric properties and it 
is, thus, a reliable and valid tool for the multidimensional 
assessment of children with JIA.
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